Restricted accessResearch articleFirst published online 2011-09
Resistance-Associated Mutation Prevalence According to Subtypes B and Non-B of HIV Type 1 in Antiretroviral-Experienced Patients in Minas Gerais,Brazil
The emergence of resistance-associated mutations to the antiretroviral agents and the genetic variability of HIV-1 impose challenges to therapeutic success. We report the results of genotype testing assays performed between 2002 and 2006 in 240 antiretroviral-experienced patients followed up in an HIV reference center in Brazil. Drug resistance mutations and viral subtypes were assessed through the algorithms from the Brazilian Genotyping Network (RENAGENO—Brazil) and from Stanford University. Mutation 184VI was the most prevalent (70%) and the thymidine analogue mutations that appeared most frequently were 215FY, 41L, 67N, and 210W, in this order. Among nonnucleoside reverse transcriptase inhibitor mutations, 103NS (32.5%) stood out. HIV subtype B was identified in 184 patients (76.7%). A significant increasing trend in the prevalence of non-B subtypes was observed during the study period (p=0.004). The main differences in prevalence of mutations among HIV-1 subtypes were related to viral protease, with 20MRI, 36I, and 89IMT more prevalent among non-B subtypes, and 84V, 10FR, 63P, 71LTV, and 77I more common in subtype B (p<0.05). Most mutations to etravirine had a prevalence lower than 10%, but at least one mutation to this drug was observed in 45% of the patients. In only 11 patients (4.6%) three mutations to etravirine were verified. Regional surveillance of the resistance profile and HIV-1 subtypes is crucial in the context of public health, to prevent the transmission of resistant strains and to guide the introduction of new drugs in a specific population.
Get full access to this article
View all access options for this article.
References
1.
MarinsJR, JamalLF, ChenSYet al.Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS, 2003; 17:1675–1682.
2.
PuhanMA, Van NattaML, PalellaFJ, AddessiA, MeinertC. Ocular Complications of AIDS Research Group. Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: Temporal changes and risk factors. Clin Infect Dis, 2010; 51:947–956.
3.
Ministério da Saúde—Brasil: Programa Nacional DST/AIDS. Recomendações para terapia antiretroviral em adultos e adolescentes infectados pelo HIV, 2008. www.aids.gov.br/renageno.
4.
HirschMS, GunthardHF, SchapiroJMet al.Antiretroviral drug resistance testing in adults with HIV infection: 2008 recommendations of an International AIDS Society—USA Painel. Clin Infect Dis, 2008; 47:266–285.
5.
ShaferRW, SchapiroJM. HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev, 2008; 10:67–84.
6.
CostagliolaD, DescampsD, AssoumouLet al.Prevalence of HIV-1 drug resistance in treated patients: A French nationwide study. J Acquir Immune Defic Syndr, 2007; 46:12–18.
7.
Couto-FernandezJC, Silva-de-JesusC, VelosoVGet al.Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: Assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy. Mem Inst Oswaldo Cruz, 2005; 100:73–78.
8.
CavalcantiAMS, LacerdaHR, BritoAM, PereiraS, MedeirosD, OliveiraS. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the northeast region of Brazil. Mem Inst Oswaldo Cruz, 2007; 102:785–792.
9.
MaL, SunJ, XingHet al.Genotype and phenotype patterns of drug-resistant HIV-1 subtype B (Thai B) Isolated from patients failing antiretroviral therapy in China. J Acquir Immune Defic Syndr, 2007; 44:14–19.
10.
García-GuerreroJ, Sáiz de la HoyaP, PortillaJet al.Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates. Eur J Clin Microbiol Infect Dis, 2006; 25:695–701.
11.
HoggRS, BangsbergDR, LimaVDet al.Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med, 2006; 3:e356.
12.
RecskyMA, BrummeZL, ChanKJet al.Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis, 2004; 190:285–292.
13.
LucasGM, GallantJE, MooreRD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS, 2004; 18:1539–1548.
14.
MuneratoP, SucupiraMC, OliveirosMPet al.HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the city of São Paulo, Brazil. AIDS Res Hum Retroviruses, 2010; 26:265–272.
15.
ZaccarelliM, TozziV, LorenziniPet al.Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS, 2005; 19:1081–1089.
16.
ZaccarelliM, TozziV, LorenziniPet al.The V118I mutation as a marker of advanced HIV infection and disease progression. Antivir Ther, 2007; 12:163–168.
17.
Martfnez-CajasJL, Pant-PaiN, KleinMB, WainbergMA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: A systematic review of virologic and biochemical evidence. AIDS Rev, 2008; 10:212–223.
18.
HolguínA, LópezM, SorianoV. Reliability of rapid subtyping tools compared to that of phylogenetic analysis for characterization of human immunodeficiency virus type 1 non-B subtypes and recombinant forms. J Clin Microbiol, 2008; 46:3896–3899.
19.
YebraG, de MulderM, MartinLet al.Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS)Antiviral Res, 2011; 89:19–25.
20.
BrindeiroRM, DiazRS, SabinoECet al.Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): A survey of chronically infected individuals. AIDS, 2003; 17:1063–1069.
21.
CerqueiraDM, AmorimRM, SilvaRR, CamaraGN, BrfgidoMM, MartinsCR. Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. Mem Inst Oswaldo Cruz, 2004; 99:877–882.
22.
AraujoAD, BritesC, Monteiro-CunhaJ, SantosLA, Galvao-CastroB, AlcantaraLC. Lower prevalence of human imunodeficiency virus type 1 Brazilian subtype B found in northeastern Brazil with slower progression to AIDS. AIDS Res Hum Retroviruses, 2010; 26:1249–1254.
23.
De Sa-FilhoDJ, AmbarRF, DuarteNBet al.HIV type 1 diversity from newly diagnosed patients in Santos Metropolitan Area/Brazil. AIDS Res Hum Retroviruses, 2009; 25:925–929.
24.
CardosoLP, QueirozBB, StefaniMM. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from central west Brazil. J Clin Virol, 2009; 46:134–139.
25.
SoaresEA, MartinezAM, SouzaTMet al.HIV-1 subtype C dissemination in southern Brazil. AIDS, 2005; 19:S81–S86.
26.
Da SilvaMM, TellesFQ, da CunhaCA, RhameFS. HIV subtype, epidemiological and mutational correlations in patients from Paraná, Brazil. Braz J Infect Dis, 2010; 14,5:495–501.
27.
InocencioLA, PereiraAA, SucupiraMCet al.Brazilian Network for HIV Drug Resistance Surveillance: A survey of individuals recently diagnosed with HIV. J Int AIDS Soc, 2009; 12:20.
28.
BrigidoLF, FerreiraJL, AlmeidaVCet al.Southern Brazil HIV type 1 C expansion into the State of São Paulo, Brazil. AIDS Res Human Retroviruses Online Ahead of Print, October15, 2010, 10.1089/aid.2010.0157.
29.
De Sa-FilhoDJ, SoaresMS, CandidoVet al.HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil. AIDS Res Hum Retroviruses, 2008; 24:347–353.
30.
FerreiraFGF, PintoJA, KakehasiFMet al.Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically infected children in Belo Horizonte, Brazil. AIDS Res Hum Retroviruses, 2010; 26:229–232.
31.
TupinambásU, AleixoA, GrecoDB. HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment. Braz J Infect Dis, 2005; 9:324–329.
32.
KantorR, KatzensteinD. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev, 2003; 5:25–35.
33.
KantorR, KatzensteinDA, EfronBet al.Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med, 2005; 2:e112.
